Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Hum Vaccin Immunother ; 20(1): 2355037, 2024 Dec 31.
Article in English | MEDLINE | ID: mdl-38813652

ABSTRACT

BACKGROUND: In recent years, infectious diseases like COVID-19 have had profound global socio-economic impacts. mRNA vaccines have gained prominence due to their rapid development, industrial adaptability, simplicity, and responsiveness to new variants. Notably, the 2023 Nobel Prize in Physiology or Medicine recognized significant contributions to mRNA vaccine research. METHODS: Our study employed a comprehensive bibliometric analysis using the Web of Science Core Collection (WoSCC) database, encompassing 5,512 papers on mRNA vaccines from 2003 to 2023. We generated cooperation maps, co-citation analyses, and keyword clustering to evaluate the field's developmental history and achievements. RESULTS: The analysis yielded knowledge maps highlighting countries/institutions, influential authors, frequently published and highly cited journals, and seminal references. Ongoing research hotspots encompass immune responses, stability enhancement, applications in cancer prevention and treatment, and combating infectious diseases using mRNA technology. CONCLUSIONS: mRNA vaccines represent a transformative development in infectious disease prevention. This study provides insights into the field's growth and identifies key research priorities, facilitating advancements in vaccine technology and addressing future challenges.


Subject(s)
Bibliometrics , COVID-19 , mRNA Vaccines , Humans , COVID-19/prevention & control , COVID-19/immunology , Vaccines, Synthetic/immunology , Vaccines, Synthetic/administration & dosage , COVID-19 Vaccines/immunology , COVID-19 Vaccines/administration & dosage , Biomedical Research/trends , Vaccine Development , SARS-CoV-2/immunology , SARS-CoV-2/genetics , RNA, Messenger/genetics
2.
Bioorg Med Chem Lett ; 21(11): 3399-403, 2011 Jun 01.
Article in English | MEDLINE | ID: mdl-21524576

ABSTRACT

Herein we describe the discovery of compounds that are competitive antagonists of the CP101-606 binding site within the NR2B subtype of the NMDA receptor. The compounds identified do not possess phenolic functional groups such as those in ifenprodil and related analogs. Initial identification of hits in this series focused on a basic, secondary amine side chain which led to good potency, but also presented a hERG liability. Further modifications led to examples of non-basic replacements which demonstrated much less liability in this regard. Finally, one compound in the series, 6a, was tested in the mouse forced swim depression assay and found to show activity (s.c. 60 mg/kg).


Subject(s)
Antidepressive Agents/chemical synthesis , Pyrazines/chemical synthesis , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Antidepressive Agents/chemistry , Antidepressive Agents/pharmacology , Binding Sites , Binding, Competitive , Dose-Response Relationship, Drug , Inhibitory Concentration 50 , Mice , Molecular Structure , Motor Activity/drug effects , Protein Binding/drug effects , Pyrazines/chemistry , Pyrazines/pharmacology
3.
Acta Crystallogr Sect E Struct Rep Online ; 66(Pt 6): o1293, 2010 May 08.
Article in English | MEDLINE | ID: mdl-21579390

ABSTRACT

In the title compound, C(11)H(19)Cl(2)NO(2), the oxazolidine ring is in an envelope conformation with the O atom forming the flap. In the crystal structure, mol-ecules are linked by weak inter-molecular C-H⋯O hydrogen bonds, forming chains.

SELECTION OF CITATIONS
SEARCH DETAIL
...